// App-Quantinova.ai

[AB1101] : BASELINE CHARACTERISTICS OF RHEUMATOID ARTHRITIS PATIENTS STARTING CERTOLIZUMAB PEGOL THERAPY AND GLUCOCORTICOID PRESCRIPTION IN THE ECLAIR STUDY IN 20122013

Researchers

Presenter

  • A. Saraux

Principal Investigators

  • R.M. Flipo

  • F. Fagnani

  • I. Bru

  • G. Cukierman

  • J.M. Joubert

  • W. Czarlewski

  • J. Dunkel

  • J. Massol

  • B. Combe

Medical Centers

  • CHU Lapeyronie, Montpellier, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Rheumatoid arthritis

  • Dyslipidemia

  • Hypertension

  • Osteoporosis

  • Inflammatory Arthritis

  • Diabetes

Biomarkers

  • Estrogen receptor alpha

Drug/Treatment

  • Certolizumab pegol

  • Hydroxychloroquine

  • Glucocorticoid

  • Sulfasalazine

  • Oraprine

  • HWA-486

  • Thalidomide

  • Methadone hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved